{"groups":[{"description":"Idelalisib (Zydelig®) 150 mg tablet twice daily + bendamustine intravenously (starting dose of 90 mg/m\\^2 for up to 12 infusions)\n\n\\+ rituximab intravenously (375 mg/m\\^2 on Day 1 for a total of 6 infusions)","id":"FG000","title":"Idelalisib + Bendamustine + Rituximab"},{"description":"Placebo tablet twice daily + bendamustine intravenously (starting dose of 90 mg/m\\^2 for up to 12 infusions) + rituximab intravenously (375 mg/m\\^2 on Day 1 for a total of 6 infusions)","id":"FG001","title":"Placebo + Bendamustine + Rituximab"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"168"},{"groupId":"FG001","numSubjects":"80"}],"type":"Study Terminated by Sponsor"},{"reasons":[{"groupId":"FG000","numSubjects":"46"},{"groupId":"FG001","numSubjects":"8"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"24"},{"groupId":"FG001","numSubjects":"11"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"21"},{"groupId":"FG001","numSubjects":"4"}],"type":"Other Reason"},{"reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"6"}],"type":"Initiation of Other Anti-Cancer Therapy"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}],"type":"Blind Broken by Subject or Study Site"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"320"},{"groupId":"FG001","numSubjects":"155"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"53"},{"groupId":"FG001","numSubjects":"45"}],"comment":"Completed = reached primary efficacy endpoint of progressive disease or death","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"267"},{"groupId":"FG001","numSubjects":"110"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"581 participants were screened.","recruitmentDetails":"Participants were enrolled at study sites in the North America, Europe, and Asia Pacific. The first participant was screened on 02 January 2013. The last study visit occurred on 17 May 2016."}